Switch-maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma (NVALT19)

Autor: Gooijer, C.J. de, Noort, V. van der, Stigt, J.A., Baas, P., Biesma, B., Cornelissen, R., Walree, N. van, Heemst, R.C. van, Youssef-El Soud, M., Groen, H.J.M., Staal-van den Brekel, A.J., Buikhuisen, W.A., Bootsma, G.P., Dammeijer, F., Tinteren, H. van, Lalezari, F., Aerts, J.G., Burgers, J.A., NVALT19 Study Grp

Publikováno v: The Lancet Respiratory Medicine, 9(6), 585-592. ELSEVIER
The Lancet. Respiratory Medicine, 9(6), 585-592. ELSEVIER SCI LTD
The Lancet Respiratory Medicine, 9(6), 585-592. Elsevier Ltd.

BackgroundAlmost all patients with malignant mesothelioma eventually have disease progression after first-line therapy. Previous studies have investigated maintenance therapy, but none has shown a great effect. We aimed to assess the efficacy and saf

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::718539b24f3e56b95bd72fbb270432e2
https://doi.org/10.1016/s2213-2600(20)30362-3

Real life experience with nivolumab for the treatment of non-small cell lung carcinoma: Data from the expanded access program and routine clinical care in a tertiary cancer centre-The Netherlands Cancer Institute

Autor: Schouten, R.D., Muller, M., Gooijer, C.J. de, Baas, P., Heuvel, M. van den

Publikováno v: Lung Cancer, 126, 210-216
Lung Cancer, 126, pp. 210-216

Item does not contain fulltext

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ea76d5585de86872ed5464b9cd28ed68
https://hdl.handle.net/2066/200355